Semaglutide (administered by PDS290 pen-injector)
Pre-clinicalRecruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Monogenic Obesity
Conditions
Monogenic Obesity
Trial Timeline
Dec 1, 2025 → Dec 1, 2028
NCT ID
NCT07302802About Semaglutide (administered by PDS290 pen-injector)
Semaglutide (administered by PDS290 pen-injector) is a pre-clinical stage product being developed by Novo Nordisk for Monogenic Obesity. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07302802. Target conditions include Monogenic Obesity.
What happened to similar drugs?
0 of 1 similar drugs in Monogenic Obesity were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
3
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07302802 | Pre-clinical | Recruiting |
Competing Products
1 competing product in Monogenic Obesity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mibavademab | Regeneron Pharmaceuticals | Phase 3 | 47 |